NCT04835129: Phase 2: Isatuximab, Pomalidomide, Elotuzumab and Dexamethasone in RRMM (IMPEDE)
NCT04824794: Phase 1/2: GEN3014 Safety Trial in Relapsed or Refractory Hematologic Malignancies
KarMMa-RW: comparison of idecabtagene vicleucel with real-world outcomes in RRMM
NCT04798586: Phase 1: MAGNETISMM-2: Study of Elranatamab (PF-06863135) in Japanese Patients Myeloma
NCT04722146: Phase 1b - Teclistamab With Other Anticancer Therapies in Participants With Myeloma
NCT04892446: Phase 2: Study of Magrolimab Combinations in Participants With Relapsed/Refractory MM
NCT04756726: Phase 1/2: CFT7455 in Relapsed/Refractory Non-Hodgkin's Lymphoma or Multiple Myeloma
NCT04773522: Phase 1 - JNJ-64407564 in Japanese Participants With Relapsed or Refractory Myeloma
NCT04827563: Dyspnea and Cardiotoxicity in Multiple Myeloma Patients Who Receive Carfilzomib
NCT04822337: Phase 1/2 - Study of Carfilzomib, Len, Dex & Belantamab Mafodotin in Multiple Myeloma
NCT04735575: Phase 1/2: Study of EMB-06 in Participants With Relapsed or Refractory Myeloma
NCT04855929: Phase 1: Safety and Therapeutic Activity of ANV419 in RRMM - ANV419-001
NCT04814615: Phase 2: A Diagnostic Study of CD38-Targeted ImmunoPET of Myeloma
NCT04688853: Phase 1 - A Study to Investigate the Safety and Efficacy of TEG002 in RRMM
NCT04634552: Phase 2 - A Study of Talquetamab in Participants With Refractory Multiple Myeloma
NCT04674813: Phase 1 - A Study of CC-95266 in Subjects With Relapsed and/or Refractory Myeloma
NCT04570631: Phase 1: Eftozanermin Alfa (ABBV-621) + Bortezomib and Oral Dexamethasone RRMM
NCT04582539: Phase 1/2: Safety and Tolerability of INCB000928 in Myelodysplastic Synd. or Myeloma
NCT04680468: Belantamab Mafodotin as Pre- and Post-autologous Stem Cell Transplant & Maintenance